Kathleen M. Madden Provides an Overview of Targeted Therapies for Melanoma Patients
Kathleen M. Madden, MSN, FNP-BC, AOCNP®, provides an overview of treatment of melanoma with new targeted therapies.
Neoadjuvant Durvalumab Combination Misses Mark in EGFR+ NSCLC
Durvalumab Garners Similar OS, Albeit Varied PFS, Outcomes in EGFR+ and EGFR-Wildtype NSCLC Subgroups
Quizartinib Extends Overall Survival Across Multiple Subgroups in FLT3-ITD+ AML
Repotrectinib Showcases Early Intracranial Responses in Select ROS1+ NSCLC
2 Clarke Drive Cranbury, NJ 08512